Humoral and T cell immune responses over time following SARS-CoV-2 vaccination

Author:

Solopova G. G.1ORCID,Osipova E. Yu.1,Efimenko M. V.1,Nikolaev R. V.1,Begunova S. V.1ORCID,Tverdysheva E. A.1

Affiliation:

1. Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

Abstract

   In this study, we explored the development and durability of humoral and T cell immune responses among the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology staff members after vaccination with Sputnik V vaccine during the rapid spread of the novel coronavirus disease (COVID-19). The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Three weeks after the first dose of Sputnik V vaccine, anti-spike antibodies were detected in 78.0% of the study subjects. Three weeks after the second dose, anti-spike antibodies were found in 98.4% of the subjects. Three months later, the percentage of the study subjects with anti-spike antibodies fell to 82.7 %. At first, the median antibody level increased from 198.0 BAU/mL (prior to the second vaccination) to 1050.0 BAU/mL (3 weeks after the second dose of the vaccine) but then decreased to 710.7 BAU/mL by 3 months after the full vaccination. Six months after the full vaccination, spike-specific antibodies were detectable in 82.5 % of the studied samples; the median antibody level dropped significantly (to 253.0 BAU/mL). The majority of the study subjects had SARS-CoV-2-specific T cells. They were detected in 71.9 %, 73.9 % and 67.4 % of the subjects at 3 weeks, 3 months and 6 months after the completion of the vaccination course, respectively. The level of S-specific T cells reached a peak at 3 weeks after the vaccination and was found to decline at later time points. Thus, 6 months after the vaccination with Sputnik V, we observed a reduction in both humoral and T cell-mediated immune responses, and this should be taken into consideration when implementing COVID-19 infection prevention and control measures among the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology staff members.

Publisher

Fund Doctors, Innovations, Science for Children

Subject

Oncology,Hematology,Immunology,Immunology and Allergy,Pediatrics, Perinatology and Child Health

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3